semaglutide constipation class action in west virginia A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly's blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients GLP-1 Lawsuits: What to Know

Metabolic Changes Over Time Hormonal shifts, stress, and aging can all impact metabolism

GLP-1 weight loss program WeightCare Under its WeightCare program, patients can get access to GLP-1 medications like Novo Nordisk A/ S NYSE: NVO Ozempic and Wegovy or Eli Lilly and Co

a similar process can result from vasoconstricting drugs such as ergotamine, cocaine, or vasopressors

Demand for ethical and sustainable hunger suppressant options will grow

01/01/26 2026 OptumRx Wrap COB BIN 610127 Payer Sheet 07/02/25 Lynozyfic (linvoseltamab-gcpt) New drug approval July 2, 2025 - Regeneron announced the FDA approval of Lynozyfic (linvoseltamab-gcpt), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody

Keep in mind that individual outcomes with Semaglutide can differ based on factors like initial weight and lifestyle choices